DK141254B - Fremgangsmåde til fremstilling af clavulansyre eller et salt eller en ester deraf. - Google Patents

Fremgangsmåde til fremstilling af clavulansyre eller et salt eller en ester deraf. Download PDF

Info

Publication number
DK141254B
DK141254B DK167275AA DK167275A DK141254B DK 141254 B DK141254 B DK 141254B DK 167275A A DK167275A A DK 167275AA DK 167275 A DK167275 A DK 167275A DK 141254 B DK141254 B DK 141254B
Authority
DK
Denmark
Prior art keywords
clavulanic acid
salt
ester
lactamase
sodium
Prior art date
Application number
DK167275AA
Other languages
Danish (da)
English (en)
Other versions
DK167275A (no
DK141254C (no
Inventor
Thomas Trefor Howarth
Martin Cole
Christopher Reading
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27448389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK141254(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB17410/74A external-priority patent/GB1508977A/en
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of DK167275A publication Critical patent/DK167275A/da
Priority to DK287078A priority Critical patent/DK145543C/da
Priority to DK287278A priority patent/DK150488C/da
Priority to DK287378A priority patent/DK150489C/da
Priority to DK287178A priority patent/DK287178A/da
Publication of DK141254B publication Critical patent/DK141254B/da
Priority to DK286980A priority patent/DK157302C/da
Application granted granted Critical
Publication of DK141254C publication Critical patent/DK141254C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK167275AA 1974-04-20 1975-04-18 Fremgangsmåde til fremstilling af clavulansyre eller et salt eller en ester deraf. DK141254B (da)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DK287078A DK145543C (da) 1974-04-20 1978-06-26 Fremgangsmaade til fremstilling af hydrolyserbare estere af clavulansyre
DK287278A DK150488C (da) 1974-04-20 1978-06-26 Fremgangsmaade til isolering af et clavulansyresalt
DK287378A DK150489C (da) 1974-04-20 1978-06-26 Fremgangsmaade til fremstilling af et clavulansyresalt
DK287178A DK287178A (da) 1974-04-20 1978-06-26 Fremgangsmaade til fremstilling at et antibiotikum
DK286980A DK157302C (da) 1974-04-20 1980-07-02 Estere af clavulansyre til anvendelse som mellemprodukter ved fremstilling af clavulansyre eller farmaceutisk tolerable salte deraf

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB17410/74A GB1508977A (en) 1974-04-20 1974-04-20 Beta-lactam antibiotic from streptomyces clavuligerus
GB1741074 1974-04-20
GB2771574 1974-06-21
GB2771574 1974-06-21
GB4365174 1974-10-09
GB4365174 1974-10-09
GB5352574 1974-12-11
GB5352574 1974-12-11

Publications (3)

Publication Number Publication Date
DK167275A DK167275A (no) 1975-10-21
DK141254B true DK141254B (da) 1980-02-11
DK141254C DK141254C (no) 1980-08-11

Family

ID=27448389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK167275AA DK141254B (da) 1974-04-20 1975-04-18 Fremgangsmåde til fremstilling af clavulansyre eller et salt eller en ester deraf.

Country Status (26)

Country Link
US (5) US4427690A (no)
JP (7) JPS5246957B2 (no)
AR (3) AR206627A1 (no)
CA (1) CA1059050A (no)
CH (2) CH629252A5 (no)
CY (1) CY1078A (no)
DD (2) DD121799A5 (no)
DE (4) DE2559410A1 (no)
DK (1) DK141254B (no)
FI (1) FI54144C (no)
FR (1) FR2267778B1 (no)
HK (1) HK54780A (no)
IE (1) IE41109B1 (no)
IL (1) IL47087A (no)
IN (1) IN140042B (no)
KE (1) KE3076A (no)
LU (1) LU72322A1 (no)
MY (1) MY8100195A (no)
NL (1) NL163824C (no)
NO (3) NO145247C (no)
NZ (1) NZ177159A (no)
OA (1) OA05203A (no)
PH (1) PH16474A (no)
RO (2) RO77320A (no)
SE (8) SE422063B (no)
YU (3) YU39941B (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152296B (da) * 1977-03-16 1988-02-15 Beecham Group Ltd Fremgangsmaade til fremstilling af en pille, der kan anvendes ved testning af mikroorganismer
DK156069B (da) * 1979-08-24 1989-06-19 Beecham Group Ltd Anvendelse af tert.butylaminsaltet af clavulansyre som mellemprodukt ved fremstillingen af clavulansyre og farmaceutisk tolerable salte og estere deraf

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) * 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
AT353409B (de) * 1975-02-07 1979-11-12 Glaxo Lab Ltd Verfahren zum entfernen von verunreinigungen aus clavulansaeure oder deren salzen
JPS596796Y2 (ja) * 1975-04-04 1984-03-01 株式会社東芝 脱水兼用洗濯機
US6218380B1 (en) * 1975-04-17 2001-04-17 Smithkline Beecham P.L.C. Pharmaceutical compositions
US6048977C1 (en) * 1975-04-17 2001-10-16 Smithkline Beecham Plc Clavulanic acid and salts thereof
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
US4230622A (en) * 1975-12-17 1980-10-28 Glaxo Laboratories Limited Halogen derivatives of clavulaic acid
GB1515241A (en) * 1976-01-27 1978-06-21 Beecham Group Ltd Beta-lactam antibiotics
NL7706242A (nl) * 1976-06-08 1977-12-12 Glaxo Lab Ltd Werkwijze voor de bereiding van clavamderivaten.
GB1562802A (en) * 1976-06-26 1980-03-19 Beecham Group Ltd Pharmaceutical compositions containing containing clavulanic acid
GB1562902A (en) * 1976-06-30 1980-03-19 Beecham Group Ltd Pharmaceutical compositions containing clavulanic acid
GB1578739A (en) * 1976-07-23 1980-11-05 Beecham Group Ltd Amine salts of clavulanic acid methods for their preparation and compositions containing them
GB1582884A (en) * 1977-05-19 1981-01-14 Beecham Group Ltd Clavulanic acid derivatives their preparation and use
DE2912511C2 (de) * 1977-06-07 1982-06-24 Pfizer Inc., 10017 New York, N.Y. Pharmazeutische Zusammensetzung, enthaltend Penicillansäure
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
JPS54126735A (en) * 1978-03-24 1979-10-02 Toyama Chem Co Ltd Bactericidal composition for medical use
EP0008905B1 (en) * 1978-09-06 1983-02-16 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
JPS5545906U (no) * 1978-09-21 1980-03-26
US4202819A (en) * 1979-05-04 1980-05-13 Hoffman-La Roche Inc. 2-(3-Alanyl)clavam antibiotic
ZA804670B (en) * 1979-08-03 1981-07-29 Beecham Group Ltd Derivatives of clavulanic acid, a process for their preparation and their use
NZ199061A (en) * 1980-12-09 1984-10-19 Beecham Group Ltd 9-(n-tetrazolyl)-deoxyclavulanic acids,salts,esters,and pharmaceutical compositions
US4562182A (en) * 1980-12-23 1985-12-31 Beecham Group P.L.C. Compounds containing beta-lactams
JPS58361A (ja) * 1981-06-22 1983-01-05 Kurosaki Refract Co Ltd 溶融金属鋳造用ノズル
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
US4684643A (en) * 1983-08-22 1987-08-04 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
IT1207982B (it) * 1983-10-07 1989-06-01 Lisapharma Spa Composizioni farmaceutiche adattivita' antibiotica.
JPS60151610U (ja) * 1984-03-22 1985-10-08 住友重機械工業株式会社 回転ホイ−ル式連続金属押出装置におけるアバツトメント
JPS6155889A (ja) * 1984-08-28 1986-03-20 松下電器産業株式会社 高周波加熱装置
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
DE3725375A1 (de) * 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
GB9009446D0 (en) * 1990-04-26 1990-06-20 Beecham Group Plc Veterinary composition
DE4027928A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4030706A1 (de) * 1990-09-28 1992-04-02 Bayer Ag Neue 3-substituierte cephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9201639D0 (en) * 1992-01-25 1992-03-11 Smithkline Beecham Plc Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT399155B (de) * 1992-03-26 1995-03-27 Lek Tovarna Farmacevtskih Neue alkylendiammonium-diclavulanat-derivate, verfahren zu deren herstellung sowie deren verwendung
EP0680322B1 (en) * 1993-01-22 2000-07-05 Smithkline Beecham Plc Use of clavulanate and an antibacterial compound for the treatment of infections
US5821364A (en) * 1993-03-26 1998-10-13 Gist-Brocades N.V. Diamine salts of clavulanic acid
US5741903A (en) * 1993-03-26 1998-04-21 Gist-Brocades N.V. Diamine salts for purification of clavulanic acid
PL306371A1 (en) * 1993-03-26 1995-03-20 Gist Brocades Nv Diamine salts of clavulanic acid
US5760218A (en) * 1993-03-26 1998-06-02 Gist-Brocades N.V. Diamine salts of clavulanic acid
US20030219867A1 (en) * 1993-07-24 2003-11-27 Smithkline Beecham Plc Clavulanic acid dehydrogenase, preparation and use for the production of clavulanic acid
GB9315393D0 (en) 1993-07-24 1993-09-08 Smithkline Beecham Plc Novel product
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9515809D0 (en) * 1995-08-02 1995-10-04 Smithkline Beecham Plc Process
SI9500265A1 (en) 1995-08-28 1997-02-28 Lek Tovarna Farmacevtskih Process for purification of the aqueous fermented broth filtrate of streptomyces sp. p 6621 ferm p 2804 by ultrafiltration
WO1997009042A1 (en) * 1995-09-07 1997-03-13 Smithkline Beecham Corporation Pharmaceutical formulation
AT403375B (de) * 1995-11-15 1998-01-26 Biochemie Gmbh Verfahren zur fällung von alkalisalzen der clavulansäure
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
PL335227A1 (en) * 1997-02-20 2000-04-10 Dsm Nv Industrial-scale production of valuable compounds by fermentation in a chemically defined medium
AR015825A1 (es) * 1997-05-28 2001-05-30 Gist Brocades Bv Produccion fermentativa de acido clavulanico bajo condiciones controladas de fosfato
WO2000001840A1 (en) * 1998-07-03 2000-01-13 Dsm N.V. Fermentation process to produce clavulanic acid at a low concentration of free amino acids
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060194285A1 (en) * 2005-02-08 2006-08-31 Wei Lian Biological production of clavulanic acid and related compounds
DE102005009277B4 (de) * 2005-02-25 2008-07-31 Johnson Controls Interiors Gmbh & Co. Kg Halterung für eine Komponente
CA2783572C (en) * 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20070218038A1 (en) 2006-03-17 2007-09-20 Pegasus Biologics, Inc. Stabilized, sterilized collagen scaffolds with active adjuncts attached
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2575781A1 (en) 2010-06-03 2013-04-10 Mahmut Bilgic Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate
KR102147420B1 (ko) 2012-12-07 2020-08-25 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN109715156A (zh) 2016-07-14 2019-05-03 尔察祯有限公司 用于治疗细菌感染的头孢布烯和克拉维酸的组合
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
CN110959008A (zh) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
EP4049036A1 (en) 2019-10-25 2022-08-31 Instrumentation Laboratory Company Biocide compositions compatible with enzyme biosensors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801464A (en) 1972-02-09 1974-04-02 Lilly Co Eli Antibiotic a16886 and process for production thereof
IE41109B1 (en) * 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
US4140764A (en) * 1974-12-18 1979-02-20 Beecham Group Limited β-Lactamase inhibitors and process for their preparation
US4123540A (en) * 1974-12-18 1978-10-31 Beecham Group Limited Isoclavulanic acid as an antibacterial and a β-lactamase inhibitor
US4144242A (en) * 1975-02-07 1979-03-13 Glaxo Laboratories Limited Process for the purification of clavulanic acid
AT353409B (de) * 1975-02-07 1979-11-12 Glaxo Lab Ltd Verfahren zum entfernen von verunreinigungen aus clavulansaeure oder deren salzen
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152296B (da) * 1977-03-16 1988-02-15 Beecham Group Ltd Fremgangsmaade til fremstilling af en pille, der kan anvendes ved testning af mikroorganismer
DK156069B (da) * 1979-08-24 1989-06-19 Beecham Group Ltd Anvendelse af tert.butylaminsaltet af clavulansyre som mellemprodukt ved fremstillingen af clavulansyre og farmaceutisk tolerable salte og estere deraf

Also Published As

Publication number Publication date
AR216430A1 (es) 1979-12-28
SE8306328D0 (sv) 1983-11-16
RO69984A (ro) 1980-12-30
FI54144B (fi) 1978-06-30
NO145247B (no) 1981-11-02
US4525352A (en) 1985-06-25
SE8105829L (sv) 1981-10-02
US4560552C1 (en) 2001-10-16
SE435286B (sv) 1984-09-17
IL47087A0 (en) 1975-06-25
NL163824C (nl) 1980-10-15
IE41109L (en) 1975-10-20
JPS532495A (en) 1978-01-11
JPS50142591A (no) 1975-11-17
US4556559A (en) 1985-12-03
JPS5549832B2 (no) 1980-12-15
SE443562B (sv) 1986-03-03
JPS532494A (en) 1978-01-11
NO150838B (no) 1984-09-17
DE2560074C2 (de) 1985-03-28
NL7504621A (nl) 1975-10-22
IE41109B1 (en) 1979-10-24
FI54144C (fi) 1978-10-10
JPS5246957B2 (no) 1977-11-29
AR206627A1 (es) 1976-08-06
JPS521996B2 (no) 1977-01-19
US4526783A (en) 1985-07-02
CA1059050A (en) 1979-07-24
JPS533590A (en) 1978-01-13
JPS5549831B2 (no) 1980-12-15
IN140042B (no) 1976-09-04
JPS5549833B2 (no) 1980-12-15
FI751133A (no) 1975-10-21
US4560552A (en) 1985-12-24
NO145247C (no) 1982-02-10
DK167275A (no) 1975-10-21
DK141254C (no) 1980-08-11
MY8100195A (en) 1981-12-31
NZ177159A (en) 1978-03-06
JPS5549830B2 (no) 1980-12-15
AR219050A1 (es) 1980-07-31
YU274481A (en) 1983-06-30
YU42744B (en) 1988-12-31
DD132297A5 (de) 1978-09-20
RO77320A (ro) 1981-08-17
JPS533589A (en) 1978-01-13
IL47087A (en) 1979-07-25
DE2517316C2 (de) 1985-03-07
SE7811200L (sv) 1978-10-27
YU39941B (en) 1985-06-30
PH16474A (en) 1983-10-25
NO150838C (no) 1985-01-09
FR2267778A1 (no) 1975-11-14
SE7811202L (sv) 1978-10-27
SE8605405L (sv) 1986-12-16
DD121799A5 (no) 1976-08-20
YU42745B (en) 1988-12-31
OA05203A (fr) 1981-02-28
FR2267778B1 (no) 1978-11-17
CH630631A5 (de) 1982-06-30
YU90875A (en) 1982-05-31
CY1078A (en) 1980-12-27
SE435287B (sv) 1984-09-17
SE446687B (sv) 1986-10-06
KE3076A (en) 1980-10-03
NL163824B (nl) 1980-05-16
DE2517316A1 (de) 1975-10-23
NO801852L (no) 1975-10-21
NO791956L (no) 1975-10-21
SE7811201L (sv) 1978-10-27
CH629252A5 (de) 1982-04-15
LU72322A1 (no) 1975-08-20
US4427690A (en) 1984-01-24
SE422063B (sv) 1982-02-15
DE2559410A1 (de) 1976-09-23
SE8306328L (sv) 1983-11-16
HK54780A (en) 1980-10-03
DE2559411A1 (de) 1976-10-21
YU274381A (en) 1983-06-30
NO751407L (no) 1975-10-21
SE7504541L (no) 1975-12-19
SE453600B (sv) 1988-02-15
JPS50142789A (no) 1975-11-17
JPS533588A (en) 1978-01-13
SE7811203L (sv) 1978-10-27
DE2559411C2 (de) 1982-07-01
SE8605405D0 (sv) 1986-12-16

Similar Documents

Publication Publication Date Title
DK141254B (da) Fremgangsmåde til fremstilling af clavulansyre eller et salt eller en ester deraf.
US4110165A (en) Process for the production of clavulanic acid
US6218380B1 (en) Pharmaceutical compositions
US4529720A (en) Antibiotic from Streptomyces clavulicerus
US6048977A (en) Clavulanic acid and salts thereof
CS231157B2 (en) Processing method of klavulan acid and corresponding salts and esters
US4235882A (en) Antibiotic MM 4550A
DK141099B (da) Fremgangsmåde til rensning af clavulansyre eller et salt deraf med en base.
US4189473A (en) Antibiotic MM 13902
US4525353A (en) Antibiotics
US4060530A (en) Clavulanic acid amides
US4140764A (en) β-Lactamase inhibitors and process for their preparation
EP0017246B1 (en) Antibiotic pa-31088-iv, its salts with bases, a process for its manufacture, pharmaceutical compositions containing this antibiotic, streptomyces tokunonensis pa-31088 and its mutants
US4146610A (en) Antibiotics mm13902
US4123540A (en) Isoclavulanic acid as an antibacterial and a β-lactamase inhibitor
US4061649A (en) Clavulanic acid sulphates
US4172129A (en) Antibiotics
US4113856A (en) Antibiotic mm 13902
CA1074325A (en) Clavulanic acid and its salts
CA1076120A (en) Clavulanic acid esters
JPS6253157B2 (no)
JPS6210640B2 (no)
US4203973A (en) Antibiotics
DK150489B (da) Fremgangsmaade til fremstilling af et clavulansyresalt
CA1055395A (en) Antibiotics

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired